<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00803595</url>
  </required_header>
  <id_info>
    <org_study_id>CS8958-A-J301</org_study_id>
    <nct_id>NCT00803595</nct_id>
  </id_info>
  <brief_title>A Multinational Phase III Study of CS-8958 (MARVEL)</brief_title>
  <acronym>MARVEL</acronym>
  <official_title>A Randomized Double-blind Controlled Study of CS-8958 Versus Oseltamivir Phosphate in Patients With Influenza Virus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to confirm the efficacy of CS-8958 administered as a
      single inhaled low dose or single inhaled high dose by showing non-inferiority to oseltamivir
      phosphate using the time to alleviation of influenza illness. For safety evaluation,
      between-group comparisons will be made with regard to incidence of adverse events and other
      safety measures.

      In a secondary objective, the optimum dosage of CS-8958 for this indication will be evaluated
      based on the efficacy and safety of single inhaled low or high dose.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Alleviation of Influenza Illness</measure>
    <time_frame>15 days</time_frame>
    <description>The time to illness alleviation which was defined as the time from the initiation of trial treatment to the beginning of the first 21.5-h period in which all influenza symptoms were &quot;absent&quot; or &quot;mild.&quot; Patients recorded their severity of influenza symptoms (headache, myalgia/arthralgia, fatigue, chills/sweats, nasal symptom, sore throat, and cough) 4 times daily for 15 days. Patients whose influenza symptoms had not been alleviated at the time of their withdrawal from the study or at the end of the observation period were censored.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time for Body Temperature to Return to Normal</measure>
    <time_frame>15 days</time_frame>
    <description>Time for return to normal axillary temperature was was defined as the time until the beginning of the first 21.5-hour period in which the axillary temperature returned to 36.9°C. Patients recorded their axillary temperature 4 times daily for 15 days. Patients whose axillary temperature had not been returned to 36.9°C at the time of their withdrawal from the study or at the end of the observation period were censored.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1002</enrollment>
  <condition>Influenza, Human</condition>
  <arm_group>
    <arm_group_label>CS-8958 Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CS-8958 powder to be inhaled - low-dose arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CS-8958 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CS-8958 powder to be inhaled - high-dose arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oseltamivir phosphate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oseltamivir phosphate oral capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CS-8958</intervention_name>
    <description>CS-8958 powder 20 mg to be inhaled one time. Oseltamivir phosphate placebo capsules 2 times per day for 5 days</description>
    <arm_group_label>CS-8958 Low Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CS-8958</intervention_name>
    <description>CS-8958 powder 40 mg to be inhaled one time. Oseltamivir phosphate placebo capsules 2 times per day for 5 days</description>
    <arm_group_label>CS-8958 High Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oseltamivir phosphate</intervention_name>
    <description>CS-8958 placebo powder to be inhaled one time. Oseltamivir phosphate oral capsules taken twice daily for 5 days.</description>
    <arm_group_label>Oseltamivir phosphate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of influenza

          -  Axillary temperature of &gt; or = to 37.5 degrees C

        Exclusion Criteria:

          -  Infection by bacteria species and/or virus other than influenza virus

          -  Chronic respiratory disease

          -  Renal dysfunction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Hong-Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2008</study_first_submitted>
  <study_first_submitted_qc>December 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2008</study_first_posted>
  <results_first_submitted>October 12, 2011</results_first_submitted>
  <results_first_submitted_qc>October 12, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 22, 2011</results_first_posted>
  <last_update_submitted>November 29, 2011</last_update_submitted>
  <last_update_submitted_qc>November 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Neuraminidase inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oseltamivir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This multicenter, double-blind,randomized, active-controlled trial was conducted from November 2008 through March 2009 at 117 institutions in Japan, Taiwan, Korea, and China (Hong Kong).</recruitment_details>
      <pre_assignment_details>Full analysis set (FAS) was defined as the set of subjects who had a positive test result using the influenza rapid diagnostic kit, received at least 1 dose of the study drug, and had valid efficacy data. The data for the baseline characteristics is provided for this analysis set, not for all participants who entered the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CS-8958 High Dose 40 mg</title>
          <description>CS-8958 powder to be inhaled - high-dose arm</description>
        </group>
        <group group_id="P2">
          <title>CS-8958 Low Dose 20 mg</title>
          <description>CS-8958 powder to be inhaled - low-dose arm</description>
        </group>
        <group group_id="P3">
          <title>Oseltamivir 75 mg</title>
          <description>oseltamivir phosphate oral capsules</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="337"/>
                <participants group_id="P2" count="327"/>
                <participants group_id="P3" count="338"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="322"/>
                <participants group_id="P2" count="319"/>
                <participants group_id="P3" count="322"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CS-8958 High Dose 40 mg</title>
          <description>CS-8958 powder to be inhaled - high-dose arm</description>
        </group>
        <group group_id="B2">
          <title>CS-8958 Low Dose 20 mg</title>
          <description>CS-8958 powder to be inhaled - low-dose arm</description>
        </group>
        <group group_id="B3">
          <title>Oseltamivir 75 mg</title>
          <description>oseltamivir phosphate oral capsules</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="334"/>
            <count group_id="B2" value="326"/>
            <count group_id="B3" value="336"/>
            <count group_id="B4" value="996"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.9" spread="11.5"/>
                    <measurement group_id="B2" value="35.6" spread="11.7"/>
                    <measurement group_id="B3" value="34.7" spread="11.3"/>
                    <measurement group_id="B4" value="35.0" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="155"/>
                    <measurement group_id="B2" value="164"/>
                    <measurement group_id="B3" value="158"/>
                    <measurement group_id="B4" value="477"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="179"/>
                    <measurement group_id="B2" value="162"/>
                    <measurement group_id="B3" value="178"/>
                    <measurement group_id="B4" value="519"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="334"/>
                    <measurement group_id="B2" value="326"/>
                    <measurement group_id="B3" value="336"/>
                    <measurement group_id="B4" value="996"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="63"/>
                    <measurement group_id="B4" value="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="263"/>
                    <measurement group_id="B2" value="256"/>
                    <measurement group_id="B3" value="266"/>
                    <measurement group_id="B4" value="785"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Laboratory confirmed influenza</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Virus A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="218"/>
                    <measurement group_id="B2" value="215"/>
                    <measurement group_id="B3" value="212"/>
                    <measurement group_id="B4" value="645"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Virus A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="112"/>
                    <measurement group_id="B4" value="322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Virus B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Alleviation of Influenza Illness</title>
        <description>The time to illness alleviation which was defined as the time from the initiation of trial treatment to the beginning of the first 21.5-h period in which all influenza symptoms were “absent” or “mild.” Patients recorded their severity of influenza symptoms (headache, myalgia/arthralgia, fatigue, chills/sweats, nasal symptom, sore throat, and cough) 4 times daily for 15 days. Patients whose influenza symptoms had not been alleviated at the time of their withdrawal from the study or at the end of the observation period were censored.</description>
        <time_frame>15 days</time_frame>
        <population>Full analysis set (FAS) was defined as the set of subjects who had a positive test result using the influenza rapid diagnostic kit, received at least 1 dose of the study drug, and had valid efficacy data.</population>
        <group_list>
          <group group_id="O1">
            <title>CS-8958 High Dose 40 mg</title>
            <description>CS-8958 powder to be inhaled - high-dose arm</description>
          </group>
          <group group_id="O2">
            <title>CS-8958 Low Dose 20 mg</title>
            <description>CS-8958 powder to be inhaled - low-dose arm</description>
          </group>
          <group group_id="O3">
            <title>Oseltamivir 75 mg</title>
            <description>oseltamivir phosphate oral capsules</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Alleviation of Influenza Illness</title>
          <description>The time to illness alleviation which was defined as the time from the initiation of trial treatment to the beginning of the first 21.5-h period in which all influenza symptoms were “absent” or “mild.” Patients recorded their severity of influenza symptoms (headache, myalgia/arthralgia, fatigue, chills/sweats, nasal symptom, sore throat, and cough) 4 times daily for 15 days. Patients whose influenza symptoms had not been alleviated at the time of their withdrawal from the study or at the end of the observation period were censored.</description>
          <population>Full analysis set (FAS) was defined as the set of subjects who had a positive test result using the influenza rapid diagnostic kit, received at least 1 dose of the study drug, and had valid efficacy data.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="326"/>
                <count group_id="O3" value="336"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.0" lower_limit="68.4" upper_limit="80.8"/>
                    <measurement group_id="O2" value="85.8" lower_limit="76.5" upper_limit="92.8"/>
                    <measurement group_id="O3" value="73.6" lower_limit="68.5" upper_limit="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This trial was designed to confirm the efficacy of laninamivir octanoate by showing that the median time to illness alleviation in patients treated with laninamivir octanoate was not &gt;18 hours longer than that in patients treated with oseltamivir. Sample size of 300 patients in each group was determined to achieve a power of at least 80% to show noninferiority at both dose levels of laninamivir octanoate with use of a Monte Carlo simulation.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A noninferiority margin of 18 hours (h) was set to assure the superiority of laninamivir octanoate over a putative placebo. A meta-analysis using 3 placebo-controlled trials reported that the difference between the median time to illness alleviation in the placebo and oseltamivir groups was 33.1 h and the 95% confidence interval ranged from 19.1 to 47.1 h. From this, a margin that was less than the lower limit of this 95% CI was selected.</non_inferiority_desc>
            <p_value>0.748</p_value>
            <p_value_desc>2-sided p-value without adjustments for multiple testing</p_value_desc>
            <method>Generalized Wilcoxon Test</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.9</ci_lower_limit>
            <ci_upper_limit>6.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis was that there was no difference in the time to illness alleviation</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.038</p_value>
            <p_value_desc>2-sided p-value without adjustments for multiple testing</p_value_desc>
            <method>Generalized Wilcoxon Test</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-12.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.2</ci_lower_limit>
            <ci_upper_limit>-0.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This trial was designed to confirm the efficacy of laninamivir octanoate by showing that the median time to illness alleviation in patients treated with laninamivir octanoate was not &gt;18 hours longer than that in patients treated with oseltamivir. Sample size of 300 patients in each group was determined to achieve a power of at least 80% to show noninferiority at both dose levels of laninamivir octanoate with use of a Monte Carlo simulation.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A noninferiority margin of 18 hours was set to assure the superiority of laninamivir octanoate over a putative placebo. A meta-analysis using 3 placebo-controlled trials reported that the difference between the median time to illness alleviation in the placebo and oseltamivir groups was 33.1 h and the 95% confidence interval ranged from 19.1 to 47.1 h. From this, a margin that was less than the lower limit of this 95% CI was selected.</non_inferiority_desc>
            <p_value>0.104</p_value>
            <method>Generalized Wilcoxon test</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>12.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.5</ci_lower_limit>
            <ci_upper_limit>17.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time for Body Temperature to Return to Normal</title>
        <description>Time for return to normal axillary temperature was was defined as the time until the beginning of the first 21.5-hour period in which the axillary temperature returned to 36.9°C. Patients recorded their axillary temperature 4 times daily for 15 days. Patients whose axillary temperature had not been returned to 36.9°C at the time of their withdrawal from the study or at the end of the observation period were censored.</description>
        <time_frame>15 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CS-8958 High Dose 40 mg</title>
            <description>CS-8958 powder to be inhaled - high-dose arm</description>
          </group>
          <group group_id="O2">
            <title>CS-8958 Low Dose 20 mg</title>
            <description>CS-8958 powder to be inhaled - low-dose arm</description>
          </group>
          <group group_id="O3">
            <title>Oseltamivir 75 mg</title>
            <description>oseltamivir phosphate oral capsules</description>
          </group>
        </group_list>
        <measure>
          <title>Time for Body Temperature to Return to Normal</title>
          <description>Time for return to normal axillary temperature was was defined as the time until the beginning of the first 21.5-hour period in which the axillary temperature returned to 36.9°C. Patients recorded their axillary temperature 4 times daily for 15 days. Patients whose axillary temperature had not been returned to 36.9°C at the time of their withdrawal from the study or at the end of the observation period were censored.</description>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="326"/>
                <count group_id="O3" value="336"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.3" lower_limit="46.6" upper_limit="64.0"/>
                    <measurement group_id="O2" value="58.0" lower_limit="52.3" upper_limit="66.9"/>
                    <measurement group_id="O3" value="54.7" lower_limit="48.2" upper_limit="62.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis was that there was no difference in the time for return to normal axillary temperature.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.318</p_value>
            <p_value_desc>2-sided P value without adjustments for multiple testing.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>3.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.8</ci_lower_limit>
            <ci_upper_limit>9.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis was that there was no difference in the time for return to normal axillary temperature.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.981</p_value>
            <p_value_desc>2-sided P value without adjustments for multiple testing.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.8</ci_lower_limit>
            <ci_upper_limit>5.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis was that there was no difference in the time for return to normal axillary temperature.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.344</p_value>
            <p_value_desc>2-sided P value without adjustments for multiple testing.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-2.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.1</ci_lower_limit>
            <ci_upper_limit>3.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>15 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>CS-8958 High Dose 40 mg</title>
          <description>CS-8958 powder to be inhaled - high-dose arm</description>
        </group>
        <group group_id="E2">
          <title>CS-8958 Low Dose 20 mg</title>
          <description>CS-8958 powder to be inhaled - low-dose arm</description>
        </group>
        <group group_id="E3">
          <title>Oseltamivir 75 mg</title>
          <description>oseltamivir phosphate oral capsules</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Japan (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="336"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="336"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Wallenberg syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="336"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA Japan (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="63" subjects_at_risk="336"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="336"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="336"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="336"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="336"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="336"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="336"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increase</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="336"/>
              </event>
              <event>
                <sub_title>Platelet count increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="336"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="336"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="336"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="337"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="326"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="336"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Principle investigator shall not publish the results of the study at any time without the prior written approval of Sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Howard Kessler</name_or_title>
      <organization>Daiichi Sankyo Pharma Development</organization>
      <phone>732-590-5032</phone>
      <email>hmkessler@dsi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

